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Abstract
Objective: The regenerative potential of bone marrow-derived mononuclear cells (MNCs) and CD133+ stem cells 
in the heart varies in terms of their pro-angiogenic effects. This phase II/III, multicenter and double-blind trial is 
designed to compare the functional effects of intramyocardial autologous transplantation of both cell types and 
placebo in patients with recent myocardial infarction (RMI) post-coronary artery bypass graft.
Materials and Methods: This was a phase II/III, randomized, double-blind, placebo-controlled trial COMPARE 
CPM-RMI (CD133, Placebo, MNCs - recent myocardial infarction) conducted in accordance with the Declaration 
of Helsinki that assessed the safety and efficacy of CD133 and MNCs compared to placebo in patients with 
RMI. We randomly assigned 77 eligible RMI patients selected from 5 hospitals to receive CD133+ cells, MNC, 
or a placebo. Patients underwent gated single photon emission computed tomography assessments at 6 and 18 
months post-intramyocardial transplantation. We tested the normally distributed efficacy outcomes with a mixed 
analysis of variance model that used the entire data set of baseline and between-group comparisons as well as 
within subject (time) and group×time interaction terms. 
Results: There were no related serious adverse events reported. The intramyocardial transplantation of both 
cell types increased left ventricular ejection fraction by 9% [95% confidence intervals (CI): 2.14% to 15.78%, 
P=0.01] and improved decreased systolic wall thickening by -3.7 (95% CI: -7.07 to -0.42, P=0.03). The CD133 
group showed significantly decreased non-viable segments by 75% (P=0.001) compared to the placebo and 60% 
(P=0.01) compared to the MNC group. We observed this improvement at both the 6- and 18-month time points.   
Conclusion: Intramyocardial injections of CD133+ cells or MNCs appeared to be safe and efficient with superiority of 
CD133+ cells for patients with RMI. Although the sample size precluded a definitive statement about clinical outcomes, 
these results have provided the basis for larger studies to confirm definitive evidence about the efficacy of these cell 
types (Registration Number: NCT01167751).            
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Introduction
Autologous bone marrow-derived cell therapy is under 
current investigation as a potentially promising therapy 
to treat patients with ischemic heart disease and potential 
candidates for revascularization with coronary artery 
bypass grafts (CABG) (1). The goal of this treatment is 
to improve myocardial regeneration and angiogenesis 
through administration of therapeutic cells into the peri-
infarct areas of the ischemic myocardium. Mononuclear 
cells (MNCs) (2-6) and CD133+ cells (7-18) are two major 
bone marrow-derived cells used as potential treatments 
for ischemic heart diseases. However, some studies report 
favorable outcomes whereas others indicate no beneﬁts. 
These discrepancies may be related to factors such as 
the numbers of injected cells, administration route, 
time interval from myocardial infarction (MI), type of 
injected cells, cell isolation and preparation methods, and 
assessment techniques that include echocardiography, 
single photon emission computed tomography (SPECT), 
and magnetic resonance imaging (MRI). Nevertheless, 
these types of cells are easy to harvest, simple to 
administer, ethically acceptable, and do not require 
immunosuppression (19). 
CD133+ bone marrow hematopoietic stem cells possess 
the characteristics of endothelial progenitor cells. These 
cells have the capability to differentiate into endothelial 
cells in vitro and play a role in neoangiogenesis processes 
in vivo (20, 21). Compared to non-selected bone marrow 
mononuclear cells, CD133+ cells have greater pro-
angiogenic effects due to secretion of related cytokines, 
graft-host cell interactions (22-24), and resistance to 
apoptosis (25). The efﬁcacy of intramyocardial injection 
of bone marrow-derived CD133+ cells versus MNCs in 
restoring function to an injured myocardium within an 
established infarct, however, has not been explored.
We sought to determine the functional consequences 
and clinical events that followed direct intramyocardial 
delivery of autologous bone marrow-derived MNCs and 
CD133+ cells in MI patients in this phase II/III multicenter, 
randomized, double-blind, placebo-controlled study. 
Findings from a comparison of CD133+ cells or MNCs 
versus placebo in the COMPARE CPM-RMI (CD133, 
Placebo, MNCs)-(recent myocardial infarction) trial have 
implications for the development of cell-based therapies 
for ischemic heart failure.
Materials and Methods
Study design, enrollment and patient population
We conducted the COMPARE CPM-RMI phase II/III, 
randomized, double-blind, placebo-controlled trial of the 
safety and efﬁcacy of the cell procedure in accordance with 
the Declaration of Helsinki. This study was performed in 5 
Tehran, Iran hospitals (Baqiyatallah, Shahid Dr. Lavasani, 
Tehran Heart Center, Rajaie Cardiovascular Medical 
and Research Center, and Masih Daneshvari). The 
 Cell J, Vol 20, No 2, Jul-Sep (Summer) 2018 269
Intramyocardial Tx of CD133+ vs. MNC in RMI
patients’ documentations were collected from Royan 
Institute and the appropriate, related hospital. This 
study received approval from the Ethical Committee 
of Royan Institute (reference number: p-85-106). This 
trial was registered at http://www.Clinicaltrials.gov 
(identiﬁer: NCT01167751). All patients gave written 
informed consent. 
Patients were randomized at Royan Institute beginning 
in January 2008 with follow-up visits completed in July 
2012. The flow chart shows patient eligibility (Fig.1). 
We selected 1035 patients recently diagnosed with 
ﬁrst ST-elevation myocardial infarction (STEMI). The 
inclusion and exclusion criteria is listed in detail (Table 
1). Patients aged 18 to 75 years received standard therapy 
and were chosen according to a major two-step selection 
process. Initially, each patient underwent an angiography 
evaluation that determined their eligibility for elective 
CABG. For the second step of the selection process, 
each patient underwent an eligible criteria assessment 
comprised of laboratory tests, dobutamine stress 
echocardiography, and SPECT analysis for baseline 
characteristics. Finally, we randomized 77 eligible 
patients via a computer-generated randomization 
sequence in a 1:1:1 ratio between the CD133+, the 
MNC, and placebo groups. Patients underwent bone 
marrow or sham aspirations. Patients and investigators 
not affiliated with the cell-processing laboratory were 
blinded to preparation and administration of the study 
product. Each patient had follow up visits at 6 and 18 
months after transplantation. 
Fig.1: Flow chart for patient eligibility. We selected patients with STEMI at defined intervals from 10 days to 3 months. Ineligible patients were excluded 
by angiography results among other criteria as mentioned in the diagram. We divided eligible patients into three groups: placebo, MNC, and CD133+. All 
patients were intramyocardly injected 2 cc of suspension in 10 points of the marginal zone of the infarcted muscle during open heart surgery and were 
followed by SPECT scan at 6 and 18 months. From these patients, 8 were not available for follow up and one patient from the MNC group died. 
STEMI; ST elevation myocardial infarction, CABG; Coronary artery bypass graft, PCI; Percutaneous coronary intervention, LVEF; Left ventricular ejection 
fraction, MNC; Mononuclear cells, SPECT; Single photon emission computed tomography, and *; According to sample size calculation, we considered 90 
patients for enrollment, however financial limitations forced us to stop patient recruitment. This study enrolled and randomly assigned 77 patients to 
three groups: MNC, CD133+, and placebo. 
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Table 1: Patient inclusion and exclusion criteria
Inclusion criteria
Age: 18-75 Y 
First ST elevation myocardial infarction (STEMI) 10 days -3     
months 
Post-acute myocardial infarction (AMI) left ventricular ejection 
fraction (LVEF) as assessed by    echocardiography: 20-45% 
Target lesion must be located in the left anterior descending 
(LAD) section
Coronary artery bypass graft (CABG) candidate 
At least 4 akinetic segments (assessed by stress 
echocardiography) 
Exclusion criteria
History of prior AMI 
Active infection, history of recurrent infection, positive test for 
syphilis (RPR), hepatitis B and C (HBsAg, anti-   HBc, anti-
HCV), HIV or HTLV-1 
Documented terminal illness or malignancy 
Documented autoimmune disease 
Pulmonary edema 
Urgent or emergency CABG 
Systolic blood pressure<80 mmHg 
4000>leukocytes (µL)>15000
AST>100 IU/L or ALT>100 IU/L 
Hemoglobin<10 g/dL 
Platelets<100,000/µL 
INR>1.8 
HBsAg; Hepatitis B surface antigen, HBc; Hepatitis B core, HCV; Hepatitis 
C virus, HIV; Human immunodeficiency virus, HTLV-1; Human T-cell 
lymphotropic virus type 1, AST; Aspartate aminotransferase, ALT; Alanine 
aminotransferase, and INR; International normalized ratio. 
Study procedures and timeline
Baseline information included results of chemistry, 
hematology and virology laboratory tests, in addition 
to SPECT and stress echocardiography. We conducted 
patient interviews to determine demographic and clinical 
variables. 
One day prior to surgery, patients in the CD133+ and 
MNC groups underwent bone marrow aspiration (150 ml) 
from their iliac crests. The isolation of CD133+ cells and 
MNCs will be described in a later section. The cells were 
suspended in 2 ml normal saline supplemented with 2% 
autologous serum. Placebo group patients underwent a 
sham aspiration procedure to ensure proper blinding of 
the treatment assignment. The sham procedure consisted 
of creating a skin incision under local anesthesia at the 
iliac crest surface.  In the placebo group, patients received 
vehicle (2 ml) comprised of normal saline supplemented 
with 2% autologous serum. The MNC and CD133+ cell 
isolation and transplantation protocol is summarized for 
the two cell therapy groups (Fig.2). 
Patients from all study groups received the injections 
at the end of the cardiopulmonary bypass and cold 
blood cardioplegic arrest, and just prior to removal of 
the aortic cross clamp. Patients received either cells 
or vehicle placebo as intramyocardial injections to 
10 sites (0.2 ml per site) at the marginal zone of the 
subepicardial infarcted area using a 22-gauge needle. 
We performed primary echocardiography and SPECT, 
as the paraclinical imagings, to locate the infarcted 
area. During the procedure, surgeons visually estimated 
the border zone of the infarct area and performed the 
injections. Lists The mean numbers of injected CD133+ 
and MNC cells were shown for these groups (Table 
2). The average number of injected cells in the 2 ml 
cell suspension was 564.63×106 (± 69.35) MNC cells 
and 8.19×106 (± 4.26) CD133+ cells per patient. Each 
patient received 1/10 of each cell suspension injected 
per site. After the myocardial cell injections, the area 
was gently massaged, followed by reperfusion. After 
the CABG, all patients remained hospitalized for a 
minimum of 4 days. Patients were evaluated at 1 week 
after CABG, then monthly for 3 months, and at 6 and 
18 months. At the long-term (6 and 18 months) follow-
ups, we assessed for safety and efficacy that included 
a clinical interview of the New York Heart Association 
(NYHA) Classification, physical examination, and 
cardiac SPECT.
Fig.2: MNCs and CD133+ cells isolation and transplantation protocols for 
CABG candidates. Patients underwent bone marrow aspiration 24 hours 
before CABG. MNCs and CD133+ cells were isolated by Ficoll density 
gradient and a CliniMACS machine. Isolated cells were analyzed by flow 
cytometry before intramyocardial injection. Patients in the placebo group 
underwent a sham aspiration procedure. 
CABG; Coronary artery bypass grafts and MNC; Mononuclear cells.
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 Table 2: Average number of cells and immunophenotyping
of the CD133+ and MNC groups
Characteristics/
patient
MNC group
n=30
Mean (SD)
CD133+ group
n=21
Mean (SD)
Bone marrow cell 
number
2.11×109 (1.62) 2.39×109 (1.42) 
Total injected cell 
number 
564.63×106 (69.35) 8.19×106 (4.26)
Injected cell number/
site
564.63×105 (69.35) 8.19×105 (4.26)
Viability (%) 98.53 (1.67) 92.91 (7.66)
CD133+ (%) 1.19 (1.21) 63.69 (17.84)
CD34+ (%) 0.20 (0.24) n.d.
CD44+ (%) 88.16 (17.57) n.d.
CD31+ (%) 42.77 (18.98) n.d.
VEGFR (%) 38.60 (26.18) n.d.
CD; Cluster of differentiation, MNC; Mononuclear cells, n.d.: Not 
determined, and VEGFR; Vascular endothelial growth factor receptor.
Objectives and endpoints
This study focused on improvement of myocardial 
perfusion and left ventricular (LV) function in STEMI 
patients after injections of bone marrow derived cells into 
the infarcted myocardium compared to a placebo group. 
Additionally, we evaluated different effects of CD133+ 
and MNC cells at determined endpoints. The primary 
endpoint was assessed by changes in global LV ejection 
fraction (LVEF) at rest by gated SPECT.  
Secondary endpoints were: i. Adverse cardiac events 
that included death, reinfarction, implantable cardioverter 
deﬁbrillator (ICD) placement, infection, and arrhythmia, 
ii. Changes in wall motion score (WMS), decreased 
systolic wall thickening (Dec. Thickening) of the 
myocardium, non-viable (NV) segments, and perfusion 
defect score (PDS) assessed by gated SPECT, and 
iii. NYHA classiﬁcation. We compared and analyzed 
endpoint data amongst the three groups during the 18 
months of follow up. 
Cell separation and flow cytometry
We isolated (150 ml) bone marrow MNCs under 
Good Manufacturing Practice (GMP) conditions. Bone 
marrow MNCs were counted by a NucleoCounter 
instrument (ChemoMetec A/S, Denmark). We isolated 
the MNCs by centrifuging the resultant bone marrow 
through a low-density gradient using Ficoll-Paque 
PREMIUM (Lymphodex, Inno-train, 002041600) 
according to the manufacturer’s protocol. Briefly, 
bone marrow samples [diluted 1:1 in phosphate-
buffered saline (PBS)] were subsequently loaded over 
a Ficoll-Paque at a 3:1 ratio and centrifuged for 30 
minutes at 400 g with no brake. Cells were collected at 
the interface and washed in PBS buffer (1:1; Milteny 
Biotech GmbH, 700-25). Cell viability and counts 
were determined by trypan blue exclusion staining and 
a NucleoCounter. 
CD133+ cells were isolated by a CliniMACS 
automated machine. The bone marrow cell suspension 
was filtered through a 200 µm filter (Baxter S.A, RMC 
5849). We used a 10% Gamunex reagent as the blocking 
antibody (100 mg/ml, Talecris Biotherapeutics, Inc.). 
A monoclonal magnetic micro-bead antibody that had 
the capability to detect CD133+ cells (Milteny Biotech 
GmbH, 172-01) was applied. The magnetically labeled 
cell bags were subsequently attached to a CliniMACS 
tubing set LS (Milltenyi Biotec GmbH) and sorted 
by a CliniMACS instrument. We assessed cell count, 
viability, and sterility, after which the positive fractions 
were centrifuged for 5 minutes at 350 g. 
We assessed for cell specific marker expressions 
in the cell populations by flow cytometry. 
Cells were stained with phycoerythrin (PE) 
or fluorescein isothiocyanate (FITC) conjugated anti-
human CD133 (293C3, Milteny Biotech GmbH, 130-
090-853), hVEGFR2/KDR (R&D Systems, FAB357P), 
CD31 (BD Biosciences, 555445), CD45/34 (BD 
Biosciences, 341071), and CD44 (BD Biosciences, 
555479) antibodies, IgG2b/RPE (BD Biosciences, 
556656), and IgG1FITC/IgG1RPE (Dako, X0932). 
Next, they were analyzed with a BD FACSCalibur flow 
cytometry system (BD Biosciences, San Jose, CA, 
USA) and software version 2.5.1 (BD Biosciences) 
by gating at 2% of the isotype control. A total of 
100,000 events were acquired for each marker and 
isotype.
 Single photon emission computed tomography and
stress echocardiography imaging
We performed SPECT analysis at baseline, then at 6 
and 18 months after transplantation. SPECT images were 
obtained approximately one hour after an intravenous 
injection of 740-925 MBq of 99mTc-sestamibi by a 
single-head camera with the following parameters: low-
energy all-purpose (LEAP) collimator, 20% symmetric 
window at 140 keV, and a 64×64 matrix. Step and shoot 
acquisition and projection images were reconstructed. We 
used AutoQUANT software version 4.3.1 (AutoQUANT, 
ADAC Laboratories, Milpitas, CA) to evaluate PDS, LVEF, 
WMS, NV, and Dec. Thickening according to a scoring 
method outlined in Figure S1 (See Supplementary Online 
Information at www.celljournal.org) (26) that follows a 
model of 17 cardiac segments. We have assessed the PDS 
variable according to 4 scores: mild hypoperfusion (1), 
moderate hypoperfusion (2), severe hypoperfusion (3), 
and absence of perfusion (4). The NV score (2) segments 
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were important for viability assessment. The 3 scores for 
abnormal movement included hypokinesia (1), akinesia 
(2), and dyskinesia (3). We assessed Dec. Thickening as 
mild (1), moderate (2), or severe (3).
Patients received intravenous injections of low-dose 
dobutamine for stress echocardiography. The stress 
echocardiography images were obtained from the 
parasternal (long and short axis) in the left lateral decubitus 
and apical (2 and 4 chamber) windows. Five variables that 
included the LVEF, left ventricular end diastolic diameter 
(LVEDD), LVE systolic diameter (LVESD), the number 
of NV segments, and WMS index were evaluated using a 
17-segment model from standard parasternal and apical 
2D echocardiography recommended by the American 
Society for Echocardiography. A total of 5 expert echo-
cardiographers blinded to the patient group assignments 
performed the measurements with the same machine type 
(GE Vivid 7 with a 3 MHz probe) in each of the 5 centers. 
Statistical analysis
We extracted the conﬁdence intervals (CIs) of outcomes 
to evaluate improvements in myocardial perfusion and 
LV function in study patients treated with CD133+ cells 
or MNC versus placebo and in patients that received 
CD133+ cells versus MNC. All statistical analyses were 
performed by taking into consideration the intention to 
treat (ITT) point of view. We used analysis of variance 
(ANOVA) for quantitative outcomes and the χ2 test for 
qualitative baseline variables to analyze for differences 
between the study groups. Normal distributed efﬁcacy 
outcomes were tested with a mixed analysis of variance 
model that used the entire data set of baseline, between-
group comparisons, within subject (time), and group×time 
interactions (27, 28). 
The NYHA class change scores (baseline vs. 18 
months) were calculated to ascertain treatment efﬁcacy 
by the χ2 test. The sample size was estimated from a study 
by Zhao et al. (29) and conservative assumptions. At least 
27 patients were considered adequate for each group; 
according to the potential for patient loss during the trial, 
we determined the total sample size as 90 with a power 
of >80%. Data analyses were performed by the repeated 
measures method, standard deviation to 9 units, and a 
minimum clinically important difference to 6 units in the 
LVEF scale as a primary end-point, with a correlation 
between 6 and 18 months to 0.6. We assumed 6 unit 
differences only for the cell therapy groups against the 
placebo. Analyses were conducted using SPSS software 
version 16 (SPSS, Chicago, IL, USA). The data have 
been presented as mean ± SD. A P<0.05 was considered 
statistically signiﬁcant. 
Results
 Patients
We considered an enrollment of 90 patients according 
to the sample size calculation. However financial 
limitations forced us to stop patient recruitment. 
Therefore, this study enrolled and randomly assigned 
77 patients to three groups: MNC, CD133+ and placebo 
through anterior STEMI at a defined time interval. 
After opening the study code, we determined that the 
numbers of patients per group were not similar: MNC 
(n=30), CD133+ (n=21) and placebo (n=26). There were 
no significant differences in baseline characteristics 
detected between groups except for coronary artery 
disease, LVESD, and LVEDD. The study population 
was predominantly male (Table 3). 
There were 9 patients who received the study intervention 
but did not complete the 18 months of follow-up. One 
patient in the CD133+ and one in the MNC group were 
lost to follow up due to relocation out of the province. 
Four patients in MNC group and two in the placebo group 
were lost to follow up due to lack of telephone access. 
One patient from the MNC group died in the ninth month 
after surgery (Fig.1). 
The average number of bone marrow MNC cells 
obtained was 2.11×109 (± 1.62) in the MNC group and 
2.39×109 (± 1.42) in the CD133+ group (Table 2). The 
average number of injected cells prepared in a 2 ml cell 
suspension of normal saline with 2% autologous serum 
was 564.63×106 ( ± 69.35) MNC cells and 8.19×106 (± 
4.26) CD133+ cells per recipient.
Safety and adverse events during follow-up
There were no reported study related serious adverse 
events during the initial hospitalization. However, 2 
patients in the placebo group experienced reinfarction at 
8 and 11 months after surgery. Additionally, 2 patients 
who had an LVEF <30% and mild-to-moderate symptoms 
of heart failure in the MNC group agreed to undergo 
ICD implantation as a primary prevention at the 6- and 
18-month post-surgery follow up visits as recommended 
by the ACC/AHA Guidelines (30). One patient in MNC 
group died from cardiac arrest during the 9th month after 
surgery. There was no autopsy performed for this patient. 
Additionally, we observed no infections or arrhythmias 
among patients from all groups. The number of total 
adverse events per group were: placebo [2], CD133+ [0], 
and MNC [3].
 Physical functional
The NYHA class improved after 18 months 
compared with baseline in 17 (85.0%) CD133+ 
patients, 18 (75.0%) MNC patients, and 13 (54.2%) 
placebo patients. There was no change in 3 (15.0%) 
CD133+ patients, 6 (25.0%) MNC patients, and 10 
(41.7%) placebo patients. There was no worsening in 
NYHA classification among the CD133+ and MNC 
patients after 18 months. However, one patient from 
the placebo group had an increase in the NYHA 
classification (P=0.178, Table S1) (See Supplementary 
Online Information at www.celljournal.org).
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Table 3: Patient baseline characteristics
Parameter Placebo group
n=26
CD133+ group
n=21
MNC group
n=30
P value
Age (Y), mean (SD) 55.50 (8.54) 53.14 (8.56) 51.45 (7.49) NS
Females, n (%)  3 (11.5) 2 (9.5) 3 (10) NS
Body mass index, mean (SD) 26.7 (4.2) 27.9 (2.6) 26.0 (2.7) NS
Duration*, (median days) 32.5 30 26.5 NS
Min-Max (day) 10-79 10-90 10-76
CAD, n (%)
   LAD only
   LAD+RCA/LCX
   LAD+RCA+LCX
2 (7.6)
4 (15.3)
20 (76.9)
0.0
6 (28.5)
15 (71.4)
5 (16.6)
11 (36.6)
14 (46.6)
0.039
Diabetes mellitus, n (%) 10 (38.4) 6 (28.5) 11 (36.6) NS
Hypertension, n (%) 6 (23.0) 7 (33.3) 6 (20.0) NS
Hyperlipidemia, n (%) 14 (53.8) 9 (42.8) 15 (50.0) NS 
Smoking, n (%) 12 (46.1) 7 (33.3) 15 (50.0) NS 
Preoperative medication, n
   Aspirin 
   Clopidogrel 
   Βeta-blockers
   ACE inhibitors
   Statins
   Nitrates  
   Diuretic 
   Digoxin
   Thrombolytic 
22
13
24
13
22
20
10
9
12
16
11
16
12
18
14
6
8
10
24
16
23
20
21
18
8
7
14
NS
Lab test (U/L) [mean (SD)]
   Peak CK-total
   Peak CK-MB
774 (541)
52 (37)
924 (301)
54 (24)
646 (310)
76 (74)
NS
SPECT [mean (SD)]
   LVEF (%)
   PDS
   NV
   WMS
   Dec. Thickening
40.47 (15.12)
10.82 (9.24)
2.05 (3.12)
5.11 (3.62)
8.64 (6.86)
39.80 (10.63)
17.10 (10.25)
4.14 (3.65)
5.50 (3.74)
11.10 (4.25)
37.06 (9.01)
16.38 (9.98)
3.00 (3.31)
6.93 (5.00)
14.46 (8.55)
NS
S. echo, mean (SD)
   LVEF (%)
   NV
   WMSI
   LVEDD (mm)
   LVESD (mm)
32.90 (8.40)
5.83 (0.77)
2.00 (0.09)
55.60 (6.37)
43.98 (8.50)
31.13 (5.37)
5.96 (0.75)
2.14 (0.11)
59.19 (7.03)
46.65 (7.78)
32.34 (5.86)
6.32 (0.68)
1.96 (0.07)
53.08 (5.36)
40.68 (6.36)
NS
NS
NS
0.012
0.050
Operative details 
   Number of grafts, mean (SD)
   Lima grafts, n
   X-clamp time (minute)
   Perfusion time (minute)
3.6 (0.7)
26
39 (10)
68 (18)
3.5 (0.8)
20
46 (16)
74 (27)
3.2 (0.8)
30
45 (13)
73 (21)
NS
MNC; Mononuclear cells, CAD; Coronary artery disease, LAD; Left anterior descending, RCA; Right coronary artery, LCX; Left circumflex artery, SPECT; 
Single photon emission computed tomography, LVEF; Left ventricular ejection fraction, PDS; Perfusion defect score, NV; Non-viable segments, WMS; 
Wall motion score, Dec. Thickening; Decreased systolic wall thickening, S. echo; Stress echocardiography, WMSI; Wall motion score index, LVEDD; Left 
ventricular end diastolic diameter, LVESD; Left ventricular end systolic diameter, NS; Not significant, *; Days from myocardial infarction (MI) to coronary 
artery bypass graft (CABG). 
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Global function
We used cardiac SPECT to assess LVEF, NV segments, 
Dec. Thickening, WMS, and PDS at baseline, and 6 and 
18 months after transplantation (Fig.3, Table S2) (See 
Supplementary Online Information at www.celljournal.
org). Analysis of the parameters showed consistent results 
at both time points. LVEF increased by 9% in CD133+ 
group (95% CI: 2.14% to 15.78%, P=0.011) and 7% in 
the MNC group (95% CI: 1.05% to 12.79%, P=0.022) 
relative to the placebo group. 
NV segments decreased by 75% equals to -1.5 (95% CI: 
-2.33 to -0.62, P=0.001) after administration of CD133+ 
cells, yet remained unchanged with MNC -0.30 (95% 
CI: -1.09 to 0.48, P=0.443) compared to the placebo. 
Additionally, the NV segments in the CD133+ group 
signiﬁcantly decreased 60% equals to -1.2 (95% CI: -2.06 
to -0.29, P=0.010) compared to MNC group. 
During the 18 months follow up, we observed 
significantly improved Dec. Thickening in both the 
CD133+ and MNC groups with a mean change of -3.75 
(95% CI: -7.07 to -0.42, P=0.028) for the CD133+ 
group and -3.55 (95% CI: -6.61 to -0.49, P=0.024) 
for the MNC group. These improvements remained 
consistent up to the 18-month follow up (P<0.05). 
Significant differences existed between the MNC 
and placebo groups in LVEF and Dec. thickening. 
We observed comparable results in the CD133+ 
versus placebo groups.  Additionally, there were no 
significant differences between the CD133+ and MNC 
groups except in NV segments in CD133+ group. 
We assessed the correlations of baseline factors (smoking, 
diabetes mellitus, hyperlipidemia, and hypertension) with 
treatment response in all three groups. Patients who smoked 
in all three groups showed a 7% decrease in LVEF (P=0.046). 
We observed no correlation in the other variables. 
Fig.3: Comparing end-point analyses of different variables between 6 and 18 months by SPECT. Significant differences existed between the cell therapy and placebo 
groups in ejection fraction, non-viable segments and decreased systolic wall thickening variables as measured by SPECT. There was no time effect observed. 
Therefore, we considered statistical significance for both the 6- and 18-month time periods. Significant difference between the cell and placebo groups. 
a; P<0.03, CD133+ or MNC groups versus placebo, +; P<0.01, significant difference between CD133+ and MNC groups. Data markers represent means + 
SD, and 95% CIs. ANOVA was conducted with repeated measures. CI; Confidence interval, MNC; Mononuclear cells, and SPECT; Single photon emission 
computed tomography.
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 Discussion
Clinical trials of intramyocardial bone marrow-derived 
cell injections have not reported any related serious 
adverse events, which this offers promise for MI (2-
18). However, the efﬁcacies of both MNCs and CD133+ 
cell transplantations remain uncertain. We designed the 
COMPARE CPM-RMI study with the intent to provide 
a placebo-controlled, double-blinded, safety and efﬁcacy 
assessments of two leading candidates for cardiac cell 
therapy include bone marrow-derived non-selected 
MNCs and selected CD133+ cells. 
The MIXED model of the COMPARE CPM-RMI data 
suggested that CD133+ cells had slightly greater efﬁcacy 
compared to MNCs. However, these ﬁndings were limited 
by the small sample size which resulted in preliminary 
conclusions. The variance-covariance matrix repeated 
measure analysis was assumed. Due to the type I error 
rate of 0.05% and observed differences in the treatment 
groups, 17 samples per arm were considered adequate 
to achieve an 80% power. Hence, the sample size and 
power of study were considered reliable despite the study 
limitations. 
CD133+ cells decreased NV segments within the 
myocardium, which suggested a possible efﬁcacy. The 
function of CD133+ cells in decreasing of NV segments 
and improving LVEF and systolic wall thickening remains 
to be determined. Results from animal studies show that 
transplanted cells integrate into the new environment, after 
which they form new vasculature and myocardium (11, 
19). We hypothesize that this effect may be due to cytokine 
release, graft-host interactions (22-24), anti-apoptotic 
factors (25) and stimulation of neovascularization (20, 
21) with cardiomyocyte regeneration primarily and by 
promotion of endogenous stem cell proliferation.
We did not observe any related serious adverse 
events from the intramyocardial cell injections. Since 
the ﬁrst report on bone marrow-derived cell therapy 
for the treatment of heart failure in 2001 by Orlic et 
al. (31) numerous studies have used intracoronary, 
transendocardial, and/or intramyocardial injections. 
These trials indicated that the intramyocardial injection 
approach was the most efﬁcient method due to direct 
visualization and delivery to the target area.
In this approach, the cells localize more reliably in the 
heart (32, 33). However, with intracoronary injections 
many of the injected cells eventually localize in the lungs 
or liver.
MNCs had a mean number of 565×106 injected cells 
per recipient compared to 8×106 CD133+ cells per 
recipient. Although the number of injected CD133+ cells 
was ‎comparable in both groups, where 6.72×106 (1.19%) 
of the injected MNCs were CD133+ cells, we observed 
greater effectiveness with the enriched CD133+ cells. 
The heterogeneous population of the MNCs could affect 
homing of the desired cells, which was likely due to 
competition of multiple progenitors for engraftment and 
might reduce cell homing with well-known effects (34, 
35). Previous human studies have shown that intracoronary 
transplantation of low numbers of enriched ‎bone marrow 
progenitor cells have a 7-fold higher homing capacity 
compared to larger numbers of bone marrow-derived non-
selected MNCs (36, 37). 
On the other hand, the numbers of cells used for 
intracoronary cell therapy varied widely, even without 
taking into consideration trials that assessed the importance 
of cell number on clinical or functional outcome. We 
selected the number of CD133+ cells based on the positive 
effects of these cells that have been discussed by previous 
reports (8, 10, 11, 18) and our phase 1 clinical trial (16, 38). 
Although the therapeutic effects of at least 50 × 106 bone 
marrow-MNCs has been noted in previous meta-analyses 
(3, 39), the debate over the efﬁcacy of the numbers of cells 
continues. Some meta-analyses have found no association 
between the number of cells delivered and the outcome 
(5). Therefore, the effective number of cells has yet to be 
determined (40, 41).
Appropriate timing of cell delivery following an MI 
on the course of heart function has yet to be determined. 
Previous research on the appropriate timing of MNCs 
administered by percutaneous coronary intervention to 
patients after an acute MI (AMI) showed no detectable 
effects on recovery of regional LV function (42-44). 
Our analysis also indicated no signiﬁcant time-related 
improvements in the outcomes. 
We observed between-group efﬁcacy improvements af-
ter analyses of several outcome measures for the CD133+ 
cells and MNCs versus placebo. However, comparison be-
tween the two cell types showed no signiﬁcant differences 
in most cases, with the exception of the N.V segment vari-
able. This ﬁnding indicated that the study was not powered 
to show deﬁnitive efﬁcacy comparisons between cell types. 
Another limitation, due to ethical considerations, was the 
sham aspiration through a superﬁcial skin incision instead 
of a bone marrow harvest for placebo treated patients. We 
attempted to mimic a bone marrow aspiration procedure 
by placing patients in the prone position where they ex-
perienced the sensation of needle pressure during admin-
istration of a local anesthetic in the hip area, other related 
issues, and the intramyocardial injection of a vehicle. 
MRI is the gold standard for cardiac function and mor-
phology. However, due to limited access, our patients did 
not undergo MRI imaging. The data quality of an echocar-
diography is objective but may vary between individuals 
and centers (45). We took advantage of SPECT modality 
where the results were reported by one nuclear medicine 
specialist and double-checked by a second nuclear medi-
cine specialist. Therefore, in order to strengthen our ﬁnd-
ings, studies with more participants in conjunction with 
powerful assessments such as MRI imaging is necessary. 
Conclusion
This preliminary COMPARE CPM-RMI study showed 
the safety and possible efﬁcacy of delivering cell-therapy 
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by intramyocardial injections in patients with RMI who 
underwent CABG. These results provided the basis for 
larger studies to perform deﬁnitive assessments of the 
efﬁcacy of this approach. 
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